Comparative efficacy of tofacitinib and adalimumab in patients with psoriatic arthritis in real clinical practice. Data from the Russian nationwide register of patients with psoriatic arthritis

Comparative efficacy of tofacitinib and adalimumab in patients with psoriatic arthritis in real clinical practice. Data from the Russian nationwide register of patients with psoriatic arthritis

Objective: to compare the clinical efficacy in real clinical practice of the targeted synthetic disease-modifying antirheumatic drug (sDMARD) tofacitinib (TOFA) and the biologic DMARD (bDMARD), an inhibitor of tumor necrosis factor alpha (TNFα), adalimumab (ADA) in patients with psoriatic arthritis...

Full description

Bibliographic Details
Main Authors:	E. Yu. Loginova, T. V. Korotaeva, E. E. Gubar, Yu. L. Korsakova, S. I. Glukhova, E. A. Vasilenko, A. A. Vasilenko, N. A. Kuznetsova, I. M. Patrikeyeva, E. L. Nasonov
Format:	Article
Language:	Russian
Published:	IMA-PRESS LLC 2021-06-01
Series:	Современная ревматология
Subjects:	psoriatic arthritis tofacitinib adalimumab biologic disease-modifying antirheumatic drug targeted synthetic disease-modifying antirheumatic drug remission minimal disease activity
Online Access:	https://mrj.ima-press.net/mrj/article/view/1145

Similar Items

Achievement of minimal disease activity in psoriatic arthritis according to the time of administration of synthetic disease-modifying antirheumatic drugs, a comparative analysis of the efficacy of oral and subcutaneous methotrexate. Data from the All-Russian Psoriatic Arthritis Registry
by: T. V. Korotaeva, et al.
Published: (2021-02-01)

Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis
by: Dafna D. Gladman, MD, et al.
Published: (2020-01-01)

Tofacitinib in the treatment of active rheumatoid arthritis – single-centre experience
by: Marta Madej, et al.
Published: (2019-08-01)

Use of tofacitinib in real clinical practice to treat patients with rheumatoid arthritis resistant to synthetic and biological disease-modifying antirheumatic drugs: Results of a multicenter observational study
by: D. E. Karateev, et al.
Published: (2016-09-01)

Enthesitis is a clue to the diagnosis of spondyloarthritis, focus on psoriatic arthritis
by: Ye. D. Yehudina, et al.
Published: (2021-02-01)

Inhibitors of interleukin 17A in the treatment of psoriatic arthritis: what's new?
by: Т. V. Korotaeva
Published: (2021-04-01)

Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study
by: Marina Amaral de Ávila Machado, et al.
Published: (2018-03-01)

Cost-effectiveness analysis of active psoriatic arthritis treatment with ixekizumab in adult patients in Russian Federation health care system
by: E. A. Pyadushkina, et al.
Published: (2021-02-01)

EFFICACY AND SAFETY OF TOFACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS IN REAL CLINICAL PRACTICE
by: E. Yu. Loginova, et al.
Published: (2020-06-01)

Effect of tofacitinib treatment on active MRI sacroiliitis in psoriatic arthritis patients
by: E. E. Gubar, et al.
Published: (2021-05-01)

Switching and Discontinuation Pattern of Biologic Disease-Modifying Antirheumatic Drugs and Tofacitinib for Patients With Rheumatoid Arthritis in Taiwan
by: Ko-Jen Li, et al.
Published: (2021-07-01)

Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis: protocol of a randomized, placebo-controlled, double-blind clinical trial (COMPLETE-PsA)
by: Michelle L. M. Mulder, et al.
Published: (2020-02-01)

Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis
by: Vibeke Strand, et al.
Published: (2018-06-01)

NEW GUIDELINES FOR THE MANAGEMENT OF RHEUMATOID ARTHRITIS (EULAR, 2013): THE PLACE OF GLUCOCORTICOIDS
by: E. L. Nasonov
Published: (2015-09-01)

NEW GUIDELINES FOR THE MANAGEMENT OF RHEUMATOID ARTHRITIS (EULAR, 2013): THE PLACE OF GLUCOCORTICOIDS
by: E. L. Nasonov
Published: (2015-10-01)

NEW GUIDELINES FOR THE MANAGEMENT OF RHEUMATOID ARTHRITIS (EULAR, 2013): THE PLACE OF GLUCOCORTICOIDS
by: E. L. Nasonov
Published: (2016-12-01)

Prospects for rheumatoid arthritis pharmacotherapy: New opportunities and recommendations
by: E L Nasonov
Published: (2016-12-01)

Modern pharmacotherapy of psoriatic arthritis
by: Yu. L. Korsakova, et al.
Published: (2019-03-01)

Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate
by: Alison O’Mahony, et al.
Published: (2018-06-01)

Effect of immunomodulating treatment (usage of DMARDs) in rheumatoid arthritis on depression
by: Magdalena Kozyra, et al.
Published: (2020-08-01)

Treatment adherence to disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis
by: Xia Y, et al.
Published: (2016-05-01)

Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study
by: Kosuke Ebina, et al.
Published: (2020-06-01)

Recent evidence comparing combination of conventional synthetic disease-modifying antirheumatic drugs with biologic disease-modifying antirheumatic drugs in rheumatoid arthritis
by: Abhishek Zanwar, et al.
Published: (2017-01-01)

Rationales for discontinuation of disease-modifying antirheumatic drugs, biologic agents, and tofacitinib in rheumatoid arthritis
by: Yu. V. Muraviev, et al.
Published: (2018-12-01)

THE FIRST RUSSIAN EXPERIENCE OF ADALIMUMAB TREATMENT IN PSORIATIC ARTHRITIS
by: Elena Yurievna Loginova, et al.
Published: (2010-06-01)

GLUCOCORTICOIDS AND RHEUMATOID ARTHRITIS
by: Zhdan V. M., et al.
Published: (2020-12-01)

The clinical and pathogenetic value of Foxp3+ T regulatory cells in rheumatoid arthritis
by: A. S. Avdeeva, et al.
Published: (2016-10-01)

End-stage rheumatoid arthritis: specific features of patient management
by: Nadezhda Aleksandrovna Shostak, et al.
Published: (2013-06-01)

Rheumatoid arthritis: problems of treatment at the present stage
by: N. V. Chichasova
Published: (2018-12-01)

Description of the Clinical Case of Adalimumab and Secukinumab Therapy of a Patient with Psoriatic Arthritis
by: V. V. Didenko, et al.
Published: (2021-05-01)

Cost-minimization analysis of subcutaneous abatacept in the treatment of rheumatoid arthritis in Spain
by: R. Ariza, et al.
Published: (2014-07-01)

Biomarkers to Personalize the Treatment of Rheumatoid Arthritis: Focus on Autoantibodies and Pharmacogenetics
by: Valeria Conti, et al.
Published: (2020-12-01)

Early rheumatoid arthritis therapy: comparative characteristic of delagil, sulphasalazine and methotrexate
by: T S Salnikova, et al.
Published: (2003-08-01)

The tumor necrosis factor-α inhibitor golimumab in the treatment of rheumatoid arthritis
by: Natalia Vladimirovna Chichasova
Published: (2014-12-01)

CYCLOSPORIN A (SANDIMMUN NEORAL) IN THERAPY FOR PSORIASIS AND PSORIATIC ARTHRITIS
by: Yulia Leonodovna Korsakova
Published: (2010-09-01)

Comparative evaluation of efficacy, pharmacodynamics, and safety of Hetero’s adalimumab (Mabura®, Hetero Biopharma Ltd.) and reference adalimumab (Humira®, Abbvie Inc.) in patients with active rheumatoid arthritis on concomitant methotrexate therapy
by: Shubhadeep Sinha, et al.
Published: (2020-06-01)

Lipid profiles in rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs
by: Anna Filipowicz-Sosnowska, et al.
Published: (2014-06-01)

A Comparison of Demographics, Disease Activity, Disability, and Treatment Among Rheumatoid Arthritis Patients with and without Osteoporosis
by: Abdulkhaliq A, et al.
Published: (2021-09-01)

STRATEGY FOR DOSE REDUCTION AND DISCONTINUATION OF BIOLOGICAL AGENTS IN RHEUMATOID ARTHRITIS REMISSION
by: M. A. Kotovskaya, et al.
Published: (2018-03-01)

Mangosteen ethanol extract alleviated the severity of collagen-induced arthritis in rats and produced synergistic effects with methotrexate
by: Jian Zuo, et al.
Published: (2018-01-01)

Cannot write session to /tmp/vufind_sessions/sess_ff6qp0btpl3386d1mjnjffpbkb